Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients

被引:22
作者
Molto, Jose [1 ]
Santos, Jose R. [1 ]
Perez-Alvarez, Nuria [1 ,3 ]
Cedeno, Samandhy [2 ]
Miranda, Cristina [1 ]
Khoo, Saye [5 ]
Else, Laura [5 ]
Llibre, Josep Maria [1 ]
Valle, Marta [4 ]
Clotet, Bonaventura [1 ,2 ]
机构
[1] Hosp Univ Germans Trias & Pujol, Lluita SIDA Fdn, Badalona, Spain
[2] Hosp Univ Germans Trias & Pujol, IrsiCaixa Fdn, Badalona, Spain
[3] Univ Politecn Barcelona, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Inst Recerca, Ctr Invest Medicament, Barcelona, Spain
[5] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
关键词
D O I
10.1128/AAC.00520-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The primary outcome of the study was a viral load (VL) of < 50 copies/ml at week 48. The trough concentrations of darunavir in plasma, the number of darunavir resistance mutations, the change in the 50% inhibitory concentration (IC50) of darunavir in the virtual phenotype, and the darunavir gIQ and vIQ were correlated with the virological outcome in regression analyses adjusted by the number of active drugs in the background regimen. The VL was < 50 copies/ml in 56.8% of patients at week 48. Changes in the VL were not significantly associated with the darunavir concentration (P = 0.304), the number of darunavir resistance mutations (P = 0.695), or the change in the IC50 (P = 0.750). However, patients with darunavir vIQs of >= 1.5 had a 12-fold greater chance of achieving a >= 1 log(10) reduction in the VL (odds ratio [OR], 12.7; 95% confidence interval [95% CI], 1.9 to 81.6; P = 0.007), and a 5-fold greater chance of achieving a VL of < 50 copies/ml (OR, 5.4; 95% CI, 1.2 to 24.5; P = 0.028), at week 48 than patients with darunavir vIQs of < 1.5. The positive and negative predictive values of this darunavir vIQ cutoff for achieving a VL of < 50 copies/ml at week 48 were 70% and 69%, respectively. The darunavir vIQ predicts virological response to darunavir-based salvage therapy better than the darunavir trough concentration or resistance mutations alone. We suggest targeting a darunavir vIQ of 1.5 for achieving long-term viral suppression.
引用
收藏
页码:3928 / 3932
页数:5
相关论文
共 19 条
[1]   Predictors of virological response to atazanavir in protease inhibitor-experienced patients [J].
Barrios, A ;
Rendón, AL ;
Gallego, O ;
Martín-Carbonero, L ;
Valer, L ;
Ríois, P ;
Maida, I ;
García-Benayas, T ;
Jiménez-Nácher, I ;
González-Lahoz, J ;
Soriano, V .
HIV CLINICAL TRIALS, 2004, 5 (04) :201-205
[2]   Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients:: 24-week results of the RESIST-2 trial [J].
Cahn, Pedro ;
Villacian, Jorge ;
Lazzarin, Adriano ;
Katlama, Christine ;
Grinsztejn, Beatriz ;
Arasteh, Keikawus ;
Lopez, Paulo ;
Clumeck, Nathan ;
Gerstoft, Jan ;
Stavrianeas, Nikolas ;
Moreno, Santiago ;
Antunes, Francisco ;
Neubacher, Dietmar ;
Mayers, Douglas .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (10) :1347-1356
[3]   Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials [J].
Clotet, Bonaventura ;
Bellos, Nicholas ;
Molina, Jean-Michel ;
Cooper, David ;
Goffard, Jean-Chrostophe ;
Lazzarin, Adriano ;
Woehrmann, Andrej ;
Katlama, Christine ;
Wilkin, Timothy ;
Haubrich, Richard ;
Cohen, Calvin ;
Farthing, Charles ;
Jayaweera, Dushyantha ;
Markowitz, Martin ;
Ruane, Peter ;
Spinosa-Guzman, Sabrina ;
Lefebvre, Eric .
LANCET, 2007, 369 (9568) :1169-1178
[4]   HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients [J].
D'Avolio, Antonio ;
Siccardi, Marco ;
Sciandra, Mauro ;
Lorena, Baietto ;
Bonora, Stefano ;
Trentini, Laura ;
Di Perri, Giovanni .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 859 (02) :234-240
[5]   TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates [J].
De Meyer, S ;
Azijn, H ;
Surleraux, D ;
Jochmans, D ;
Tahri, A ;
Pauwels, R ;
Wigerinck, P ;
de Béthune, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2314-2321
[6]   Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens [J].
de Requena, Daniel Gonzalez ;
Bonora, Stefano ;
Calcagno, Andrea ;
D'Avolio, Antonio ;
Siccardi, Marco ;
Fontana, Silvia ;
Milia, Maria Grazia ;
Sciandra, Mauro ;
Garazzino, Silvia ;
Di Garbo, Antonio ;
Baietto, Lorena ;
Trentini, Laura ;
Di Perri, Giovanni .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (03) :1066-1071
[7]  
DEMEYER S, 2006, 8 INT C DRUG THER HI
[8]  
GATHE J, 2006, HIV DART 2006 FRONT, P72
[9]   Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial [J].
Gathe, Joseph ;
Cooper, David A. ;
Farthing, Charles ;
Jayaweera, Dushyantha ;
Norris, Dorece ;
Pierone, Gerald, Jr. ;
Steinhart, Corklin R. ;
Trottier, Benoit ;
Walmsley, Sharon L. ;
Workman, Cassy ;
Mukwaya, Geoffrey ;
Kohlbrenner, Veronika ;
Dohnanyi, Catherine ;
McCallister, Scott ;
Mayers, Douglas .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (10) :1337-1346
[10]  
Hoefnagel JGM, 2005, ANTIVIR THER, V10, P879